Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

NCT05405595 is registered in ClinicalTrials.gov with Adagene Inc as lead sponsor.

NCT NCT05405595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Adagene Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 15, 2022
Completion date
April 30, 2027
Enrollment
186 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors